Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Naproxen is indicated for the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain. Further, it is first-line therapy for osteoarthritis, acute gouty arthritis, dysmenorrhea, and musculoskeletal inflammation and pain.
Dallas VA Medical Center, Dallas, Texas, United States
Houston Center For Clinical Research, Houston, Texas, United States
Ironwood Investigational Site, Salt Lake City, Utah, United States
Pfizer Investigational Site, San Antonio, Texas, United States
Clinvest, Springfield, Missouri, United States
Texas Headache Associates, San Antonio, Texas, United States
Montefiore Medical Center, Bronx, New York, United States
Wellquest Clinical Research, Mumbai, Maharashtra, India
Wellquest Clinical Research, Mumbai, Maharashtra, India
Research Site, Brisbane, Queensland, Australia
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.